Measles and rubella seroimmunity in newly arrived adult immigrants in Sweden

References

• ECDC. Measles and rubella surveillance – 2017. Stockholm: European Centre for Disease Prevention and Control; 2018.
   Google Scholar
• WHO Europe. Measles and rubella elimination country profiles. [Internet]; 2018. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/publications/surveillance-and-data/measles-and-rubella-elimination-country-profiles
   Google Scholar
• Plans-Rubio P. Why does measles persist in Europe? Eur J Clin Microbiol Infect Dis. 2017;36:1899–1906.
   PubMed Web of Science ®Google Scholar
• Muscat M. Who gets measles in Europe? J Infect Dis. 2011;204(Suppl 1): S353–S365.
   PubMedGoogle Scholar
• Castelli F, Sulis G. Migration and infectious diseases. Clin Microbiol Infect. 2017;23:283–289.
   PubMed Web of Science ®Google Scholar
• Werber D, Hoffmann A, Santibanez S, et al. Large measles outbreak introduced by asylum seekers and spread among the insufficiently vaccinated resident population, Berlin, October 2014 to August 2015. Euro Surveill. 2017;22(34):pii=30599.
   Google Scholar
• Williams GA, Bacci S, Shadwick R, et al. Measles among migrants in the European Union and the European Economic Area. Scand J Public Health. 2016;44:6–13.
   PubMed Web of Science ®Google Scholar
• Jones G, Haeghebaert S, Merlin B, et al. Measles outbreak in a refugee settlement in Calais, France: January to February 2016. Euro Surveill. 2016;21:201630167.
   Google Scholar
• Jablonka A, Happle C, Grote U, et al. Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015. Infection. 2016;44:781–787.
   PubMed Web of Science ®Google Scholar
• Jablonka A, Happle C, Wetzke M, et al. Measles, rubella and varicella IgG seroprevalence in a large refugee cohort in Germany in 2015: a cross-sectional study. Infect Dis Therapy 2017;6:487–496.
   PubMed Web of Science ®Google Scholar
• Toikkanen SE, Baillot A, Dreesman J, et al. Seroprevalence of antibodies against measles, rubella and varicella among asylum seekers arriving in Lower Saxony, Germany, November 2014-October 2015. Int J Environ Res Public Health. 2016;13:650.
   Web of Science ®Google Scholar
• Hubschen JM, Charpentier E, Weicherding P, et al. IgG antibody prevalence suggests high immunization needs in newcomers to Luxembourg, 2012. Vaccine. 2018;36:899–905.
   PubMed Web of Science ®Google Scholar
• Freidl GS, Tostmann A, Curvers M, et al. Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. Vaccine. 2018;36:1664–1672.
   PubMed Web of Science ®Google Scholar
• Greenaway C, Dongier P, Boivin JF, et al. Susceptibility to measles, mumps, and rubella in newly arrived adult immigrants and refugees. Ann Intern Med. 2007;146:20–24.
   PubMed Web of Science ®Google Scholar
• De Vito EPP, de Waure C, Poscia A, et al. A review of evidence on equitable delivery, access and utilization of immunization services for migrants and refugees in the WHO European Region. Copenhagen: WHO Regional Office for Europe; 2017.
   Google Scholar
• Hargreaves S, Nellums LB, Ramsay M, et al. Who is responsible for the vaccination of migrants in Europe? Lancet. 2018;391:1752–1754.
   PubMed Web of Science ®Google Scholar
• Novo A, Huebschen JM, Muller CP, et al. Ongoing rubella outbreak in Bosnia and Herzegovina, March-July 2009–preliminary report. Euro Surveill. 2009;14:pii=19343.
   PubMedGoogle Scholar
• Hukic M, Ravlija J, Karakas S, et al. An ongoing measles outbreak in the Federation of Bosnia and Herzegovina, 2014– 2015. Euro Surveill. 2015;20:pii=21047.
   PubMedGoogle Scholar
• Salimovic-Besic I, Seremet M, Hubschen JM, et al. Epidemiologic and laboratory surveillance of the measles outbreak in the Federation of Bosnia and Herzegovina, February 2014–April 2015. Clin Microbiol Infect. 2016;22:563 e1–567.
   Web of Science ®Google Scholar
• Andrews N, Tischer A, Siedler A, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ. 2008;86:197–204.
   PubMed Web of Science ®Google Scholar
• Velicko I, Muller LL, Pebody R, et al. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. Vaccine. 2008;26:6980–6985.
   PubMed Web of Science ®Google Scholar
• Dimech W, Mulders MN. A review of testing used in seroprevalence studies on measles and rubella. Vaccine. 2016;34:4119–4122.
   PubMed Web of Science ®Google Scholar
• Byrne L, Brant L, Reynolds C, et al. Seroprevalence of low rubella IgG antibody levels among antenatal women in England tested by NHS Blood and Transplant: 2004–2009. Is rubella susceptibility increasing? Vaccine. 2012;30:161–167.
   PubMed Web of Science ®Google Scholar
• Tischer A, Andrews N, Kafatos G, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect. 2007;135:787–797.
   PubMed Web of Science ®Google Scholar
• Bouthry E, Furione M, Huzly D, et al. Assessing immunity to rubella virus: a plea for standardization of IgG (immuno)assays. J Clin Microbiol. 2016;54:1720–1725.
   PubMed Web of Science ®Google Scholar